Topoisomerase poisons target topoisomerase enzymes and interfere with the unwinding of DNA for transcription; for these reasons, they are widely used and effective chemotherapeutic agents. Tumors, however, are often insensitive to, or become resistant to, these drugs, and the genetic basis for this resistance is unclear. To identify genetic factors involved in responsernto doxorubicin (a front-line chemotherapy agent that targetsrntopoisomerase 2), Darren Burgess et al. screened a library ofrnshRNAs-molecules that knock down expression of target
展开▼
